Pathos raises $237 million at $3 billion valuation with BMS leading round
Pathos, an artificial intelligence-driven drug development company, said Friday it has raised $237 million in a Series E round led by Bristol Myers Sq
Tempus AI
Every Fin-node story mentioning Tempus AI — 1 story, newest first.
Tempus AI · 1 story